Cantitate/Preț
Produs

Emerging Non-Clinical Biostatistics in Biopharmaceutical Development and Manufacturing: Chapman & Hall/CRC Biostatistics Series

Autor Harry Yang
en Limba Engleză Paperback – 18 dec 2020
The premise of Quality by Design (QbD) is that the quality of the pharmaceutical product should be based upon a thorough understanding of both the product and the manufacturing process. This state-of-the-art book provides a single source of information on emerging statistical approaches to QbD and risk-based pharmaceutical development. A comprehensive resource, it combines in-depth explanations of advanced statistical methods with real-life case studies that illustrate practical applications of these methods in QbD implementation.
Citește tot Restrânge

Din seria Chapman & Hall/CRC Biostatistics Series

Preț: 31371 lei

Preț vechi: 35818 lei
-12% Nou

Puncte Express: 471

Preț estimativ în valută:
6004 6258$ 4998£

Carte tipărită la comandă

Livrare economică 06-20 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780367736644
ISBN-10: 0367736640
Pagini: 386
Dimensiuni: 156 x 234 mm
Greutate: 0.6 kg
Ediția:1
Editura: CRC Press
Colecția Chapman and Hall/CRC
Seria Chapman & Hall/CRC Biostatistics Series


Cuprins

BACKGROUND. Introduction. ANALYTICAL METHOD. Statistical Methods for Analytical Procedure Development, Validation and Transfer. Parallelism Testing of Bioassay. Validation of Assay Linearity. ROCESS DEVELOPMENT. Residual Host Cell DNA Risk Assessment. Statistical Evaluations of Viral Clearance. Pre-filtration Bio-burden Testing. Process Validation and Verification. MANUFACTURING. Specifications.

Notă biografică

Harry Yang, Ph.D., is senior director and head of the Non-Clinical Biostatistics Group at MedImmune, the global biologics arm of AstraZeneca headquartered in Gaithersburg, Maryland.

Descriere

The premise of Quality by Design (QbD) is that the quality of the pharmaceutical product should be based upon a thorough understanding of both the product and the manufacturing process. This state-of-the-art book provides a single source of information on emerging statistical approaches to QbD and risk-based pharmaceutical development. A compreh